1. Zagaria ME. Questionable medication benefit in advanced dementia: Decision-making tools. US Pharm. 2015;40(1):21-23.
  2. Zagaria ME. Fecal transplantation for recurrent Clostridium difficile infection. US Pharm. 2014;39(12):20-22. 
  3. Zagaria ME. Borderline personality disorder in late life: A medication adherence variable. US Pharm. 2014;39(11):25-28. 
  4. Zagaria ME. Academic detailing: Accurate, relevant, balanced, and engaging. US Pharm. 2014;39(10):16-19.  
  5. Zagaria ME. Risks for endometrial cancer: Obesity, hypertension, and diabetes. US Pharm. 2014;39(9):30,32-33.
  6. Zagaria ME. Urinary incontinence: Urologic and medication etiology in seniors. US Pharm. 2014;39(8):20-23.    
  7. Zagaria ME. Recognizing causes of dyspnea to prevent hospital admissions. US Pharm. 2014;39(7):16-18.
  8. Zagaria ME. Metatarsophalangeal Osteoarthritis: Pain in the Big Toe Joint. US Pharm. 2014;39(6):31-33.
  9. Zagaria ME. Geriatric emergency department care: The pharmacist’s role. US Pharm. 2014;39(5):18-21.
  10. Zagaria ME. Hepatitis C alert: Baby Boomers should be tested. US Pharm. 2014;39(4):18-20. 
  11. Zagaria ME. Metrics to define and measure quality pain management. US Pharm. 2014;39(3):18-21.
  12. Zagaria ME. Mechanical heart valves: Contraindication for dabigatran therapy. US Pharm. 2014;39(2)32-34.        .
  13. Zagaria ME. Head injury and chronic traumatic encephalopathy. US Pharm. 2014:39(1):20-23.
  14. Zagaria ME. Inflammatory bowel disease: Nuances of drug therapy in seniors and the role of vitamin D. US Pharm. 2013;38(12):18-20.
  15. Zagaria ME. Bleeding risk with SSRIs: Surgery and seniors. US Pharm. 2013;38(11):20-22. 
  16. Zagaria ME. Rasagiline update: Postmarket evidence and clinical considerations. US Pharm. 2013;38(10):18-20.
  17. Zagaria ME. Access to health care: Influential factors and cultural competence. US Pharm. 2013;38(9):20-22.
  18. Zagaria ME. Nephrotic syndrome: Medication and other related risks. US Pharm. 2013;38(8):18-20.
  19. Zagaria ME. Diffuse interstitial lung disease.  US Pharm. 2013;38(7):37-39.
  20. Zagaria ME. Common benign skin growths in older adults. US Pharm. 2013;38(6):37-39.   
  21. Zagaria ME. When communications become difficult: Is it dementia? US Pharm. 2013;38(5):30-32.   
  22. Zagaria ME. Antibiotic therapy: Adverse effects and dosing considerations. US Pharm. 2013:38(4):18-20.
  23. Zagaria ME. Cervical spondylosis: Neck pain, stiffness, ad associated features. US Pharm. 2013;38(3):17-19.
  24. Zagaria ME. Age-associated vulnerability and cardiovascular function: Medication Therapy Management (MTM). US Pharm. 2013;38(2):24-26. 
  25. Zagaria ME. Community-based medication management in the U.S. and Australia. US Pharm. 2013;38(1):16-18.
  26. Zagaria ME. Management of elevated INR secondary to warfarin use: Challenges, recommendations, and resources. Amer J for Nurse Practitioners. 2012;16(11/12):14-16.
  27. Zagaria ME. Laryngopharyngeal reflux (Silent Reflux). US Pharm. 2012;37(12):18-20.
  28. Zagaria ME. Vascular dementia: Potentially preventable cognitive impairment. US Pharm. 2012;37(11):22-24.
  29. Zagaria ME. Focus on the foot: Changes with age and disease. US Pharm. 2012;37(10):20-24.
  30. Zagaria ME. Potentially Inappropriate Medications in Seniors. Amer J for Nurse Practitioners. 2012;16(9/10):26-28.   
  31. Zagaria ME. Alcohol abuse and dependence in senior women: Risks and recommendations. US Pharm. 2012;37(9):22-25.
  32. Zagaria ME. Raising awareness of infectious arthritis. US Pharm. 2012;37(8):23-25.
  33. Zagaria ME. Advance directives for medical decisions. US Pharm. 2012;37(7):20-22.
  34. Zagaria ME. Medications that worsen and strategies that improve urinary incontinence. US Pharm. 2012;37(6):22-25.
  35. Zagaria ME. Pain as a barrier to exercise for successful aging. US Pharm. 2012;37(5):28-30.
  36. Zagaria ME. Actinic keratosis: Treating a potential malignancy. US Pharm. 2012;37(4):23-26.
  37. Zagaria ME. Long-distance caregiving: Challenges and tips for success. Amer J for Nurse Practitioners. 2011;16(3/4):15-18.   
  38. Zagaria ME. Syncope: Medications as cause and contributing factors. US Pharm. 2012;37(3):22,26-28.
  39. Zagaria ME. Atrial septal defect. US Pharm. 2012;37(2):29-31.
  40. Zagaria ME. Preemptive treatment of constipation when opioids are initiated. US Pharm. 2012;37(1):21-24. 
  41. Zagaria ME. Acute pancreatitis: Risks, causes, and mortality in older adults. US Pharm. 2011;36(12): 24-27. 
  42. Zagaria ME. Treatment decisions in cardiovascular disease: Focus on beta-blockers in seniors. Amer J for Nurse Practitioners. 2011;15(11/12):23-26.  
  43. Zagaria ME. Intellectual disability: Highlighting senior care issues. US Pharm. 2011;36(11):29-34.  
  44. Zagaria ME. Osteoarthritis of the hand: Focus on individualized multimodal therapy. US Pharm. 2011;36(10):22-26.
  45. Zagaria ME. Urogenital symptoms of menopause: Atrophic vaginitis and atrophic urethritis. US Pharm. 2011;36(9):22-26.
  46. Zagaria ME. Assessing and monitoring medication therapy in seniors. Amer J for Nurse Practitioners. 2011;15(9/10):48-52.  
  47. Zagaria ME. Predisposition to infection in the elderly. US Pharm. 2011;36(8): 28-32.
  48. Zagaria ME. Proton pump inhibitors: Review of benefits and fracture risk. Amer J for Nurse Practitioners. 2011;15(7/8):47-51.  
  49. Zagaria ME. Differential diagnosis of asthma and COPD in older adults: Role of spirometry. US Pharm. 2011;36(7): 20-24. 
  50. Zagaria ME. Drug- and age-related changes in sodium and water regulation. US Pharm. 2011;36(6): 30-33.
  51. Zagaria ME. Postherpetic neuralgia: Seniors at risk. US Pharm. 2011;36(5): 24-26.
  52. Zagaria ME. Herpes zoster: Treatment modalities and prevention with zoster vaccine. Amer J for Nurse Practitioners. 2011;15(5/6): 46-52.   
  53. Zagaria ME. Graves’ ophthalmopathy. US Pharm. 2011;36(4):20-29.agaria ME. Lumbar spinal stenosis. US Pharm. 2011;36(3):20-23.
  54. Zagaria ME. Lumbar spinal stenosis. US Pharm. 2011;36(3):20-23.
  55. Zagaria ME. Antipsychotic-associated metabolic and cardiovascular risks: Monitoring and risk-reduction strategies. Amer J for Nurse Practitioners. 2011;15(3/4):ahead of print.
  56. Zagaria ME. Aortic stenosis: Evidence supports surgery. US Pharm. 2011;36(2):20-25.
  57. Zagaria ME. Collaborative patient care for seniors with pain. US Pharm. 2011;36(1):21-25.
  58. Zagaria ME. Topical corticosteroids: Focus on appropriate potency and vehicle. Amer J for Nurse Practitioners. 2010;14(11/12):36-40.
  59. Zagaria ME. Gallstones: Aging and medications increase risk. US Pharm. 2010;35(12):21-24.
  60. Zagaria ME. Common adverse effects of antipsychotic agents in the elderly. US Pharm. 2010;35(11):22-26.
  61. Zagaria ME. Preventing pneumonia in seniors. US Pharm. 2010;35(10):22-25.
  62. Zagaria ME. Sarcopenia: Loss of muscle mass in older adults. US Pharm. 2010;35(9): 24-30.
  63. Zagaria ME. Vitamin deficiencies in seniors. US Pharm. 2010;35(8): 20-27.
  64. Zagaria ME. Post-Stroke aspiration pneumonia. US Pharm. 2010;35(7): 20-24.
  65. Zagaria ME. Subclinical hypothyroidism. US Pharm. 2010;35(6): 20-22.
  66. Zagaria ME. Chronic opioid therapy for noncancer pain. US Pharm. 2010;35(5): 20-24.
  67. Zagaria ME. Medications and conditions that potentiate heatstroke: Focus on seniors. Amer J for Nurse Practitioners. 2010;14(5):35-40.
  68. Zagaria ME. Kaposi’s Sarcoma: Prognosis varies with form. US Pharm. 2010;35(4):20-23.
  69. Zagaria ME. Hot flashes and night sweats. US Pharm. 2010;35(3): 20-24.
  70. Zagaria ME. Inhalant agents for asthma, bronchospasm, and COPD: Focus on delivery devices and inhalation technique. Amer J for Nurse Practitioners. 2010;14(3):21-25.
  71. Zagaria ME. Warfarin in seniors: Reducing Likelihood of harm. US Pharm. 2010;35(2): 2-22.
  72. Zagaria ME. Common causes of drug-induced seizures. US Pharm. 2010;35(1): 20-23.
  73. Zagaria ME. Colorectal cancer screening. US Pharm. 2009;34(12): 29-31.
  74. Zagaria ME. Progressive supranuclear palsy. US Pharm. 2009;34(11): 20-22.
  75. Zagaria ME. The dying patient: Choices, control, and communication – End-of-Life Care. US Pharm. 2009;34(10): 32-34.
  76. Zagaria ME. Dyslipidemia: Benefits and risks of statins in primary prevention. Amer J for Nurse Practitioners. 2009;13(10):16-22.
  77. Zagaria ME. Obesity: Reality and relevance to health. US Pharm. 2009;34(9): 20-24.
  78. Zagaria ME. Amyloidosis: Interference with organ structure and function. US Pharm. 2009;34(8): 21-24.
  79. Zagaria ME. Renal dosing: Understanding glomerular filtration rate and estimating creatinine clearance. Amer J for Nurse Practitioners. 2009;13(7/8)32-35.
  80. Zagaria ME. Raising awareness about pulmonary embolism: Risk and misdiagnosis. US Pharm. 2009;34(7): 24-26.
  81. Zagaria ME. Caring for the aging: Key health care legislation. US Pharm. 2009;34(6): 22-24.
  82. Zagaria ME. Assessing pain in the cognitively impaired. US Pharm. 2009;34(5):21-25.
  83. Zagaria ME. High-alert medications: Resources for NPs. Amer J for Nurse Practitioners. 2009;13(5):21-28.
  84. Zagaria ME. Dermatologic signs of rheumatoid arthritis: Joint and systemic symptoms. US Pharm. 2009;34(4): 22-24.
  85. Zagaria ME. Vitamin D deficiency and bone pain: Osteomalacia. US Pharm. 20009;34(3): 22-24.
  86. Zagaria ME. Medication-related problems in seniors: Risk factors and tips for appropriate prescribing. Amer J for Nurse Practitioners. 2009;13(3):23-27.
  87. Zagaria ME. Venous Thrombosis. US Pharm. 2009;34(2): 22-24.
  88. Zagaria ME. Wrist and thumb pain in seniors: Focus on De Quervain’s tenosynovitis. US Pharm. 2009;34(1): 20-22
  89. Zagaria ME. Contrast-Induced Nephropathy. US Pharm. 2008;33(12):20-22.
  90. Zagaria ME. Antipsychotics in seniors: Warnings to prevent misuse. US Pharm. 2008;33(11):20-22. 
  91. Zagaria ME. ACE inhibitors in hypertension: Dosing, comparisons, and compelling indications. Amer J for Nurse Practitioners. 2008;12(11):26-32. 
  92. Zagaria ME. Nebivolol: New beta-blocker for hypertension. US Pharm. 2008;33(10):20-26. 
  93. Zagaria ME. Health literacy: Striving for effective communication. Amer J for Nurse Practitioners. 2008;12(9):23-26. 
  94. Zagaria ME. Postmenopausal vaginal bleeding. US Pharm. 2008;33(9):28-32.
  95. Zagaria ME. Sexual activity and STDs among seniors. US Pharm. 2008;33(8):28-30. 
  96. Zagaria ME. Tuberculosis: A preventable cause of death in the elderly. US Pharm. 2008;33(7):23-25.
  97. Zagaria ME. Unintentional acetaminophen overdose: Focus on prevention. Amer J for Nurse Practitioners. 2008;12(6):47-51. 
  98. Zagaria ME. Baby boomers on brink of healthcare crisis. US Pharm. 2008;33(6):20-26.
  99. Zagaria ME. Consequences of persistent pain. US Pharm. 2008;33(5):28-30.
  100. Zagaria ME. Relapsing-remitting multiple sclerosis: Primary and symptomatic management. Amer J for Nurse Practitioners. 2008;12(4):22-26. 
  101. Zagaria ME. Cutaneous adverse reactions: Stevens-Johnson syndrome. US Pharm. 2008;33(4):20-26
  102. Zagaria ME. Diverticulitis: Overview and management. US Pharm. 2008;33(3):22-25.
  103. Zagaria ME. Adverse drug effects: Focus on SSRIs. Amer J for Nurse Practitioners. 2008;12(3):34-38.
  104. Zagaria ME. Warfarin and adverse effects. US Pharm. 2008;33(2):22-25.
  105. Zagaria ME. Causes of seizures in the elderly. US Pharm. 2008;33(1):27-31.
  106. Zagaria ME. Pediatric GER & GERD: Overview and management. Amer J for Nurse Practitioners. 2008;12(1):36-42.
  107. Zagaria ME. GERD update: The refractory patient. US Pharm. 2007;32(12):20-23.
  108. Zagaria ME. Serotonin syndrome. US Pharm. 2007;32(11):20-23.
  109. Zagaria ME. Seniors and drug development: Encouraging better communication. US Pharm. 2007;32(10):20-25 .
  110. Zagaria ME. Atypical antipsychotic agents: Monitoring for metabolic syndrome. Amer J for Nurse Practitioners. 2007;11(10):20-26.
  111. Zagaria ME. Screening for dementia in older females. US Pharm. 2007;32(9):20-25.
  112. Zagaria ME. Anticholinergic adverse effects. Amer J for Nurse Practitioners. 2007;11(9):20-25.
  113. Zagaria ME. Depression: Suicide’s primary remediable risk factor. US Pharm. 2007;32(8):22-27. .
  114. Zagaria ME. Pneumoccal Vaccine: Protecting Seniors from Pneumonia. US Pharm. 2007;32(7):22-29.
  115. Zagaria ME. Seniors at Risk for Delirium. US Pharm. 2007;32(6):20-24.
  116. Zagaria ME.. A Healthy Tan? Think Again. US Pharm Student Edition. Summer 2007.
  117. Zagaria ME. Geriatric Palliative Care: When the Focus Shifts From Care to Comfort. US Pharm. 2007;32(5):28-34.
  118. Zagaria ME. Chronic and Acute Effects of Sun Exposure on the Skin. US Pharm. 2007;32(4):20-26.
  119. Zagaria ME. Generic Medications: Issues in Senior Care Pharmacy. US Pharm Generic Drug Review. June 2007:14-15.
  120. Zagaria ME. Rate Control in Atrial Fibrillation. US Pharm. 2007;32(2):32-38.
  121. Zagaria ME. Vision, Cognition, and Mobility Challenges for Elderly Drivers. US Pharm. 2007;32(1):36-40.
  122. Zagaria ME. Family Caregiving: Seniors Continue to Receive and Deliver Care. US Pharm. 2006;31(12):23-29.
  123. Zagaria ME. Low Health Literacy: A Safety Concern Among the Elderly. US Pharm. 2006;31(10):28-34.
  124. Zagaria ME. Polypharmacy and Potentially Inappropriate Medication Use in he Elderly: Across the Practice-Setting Spectrum. US Pharm. 2006;31(10):112-116.
  125. Zagaria ME. Persistent Urinary Incontinence in Older Women: Treatment Can Improve Quality of Life. US Pharmacist 2006;31(9):20-34.
  126. Zagaria ME. Depression in Older Male Patients. US Pharmacist 2006;31(8):34-40.
  127. Zagaria ME. Management of COPD in Seniors. US Pharmacist 2006;31(7):28-34.
  128. Zagaria ME. Heat-Related Illnesses in Older Adults: Identifying Potentially Lethal Conditions. US Pharmacist 2006;31(6):34-38.
  129. Zagaria ME. Pain Assessment in Older Adults: The Cornerstone of Controlling Pain. US Pharmacist 2006;31(5):30-36
  130. Zagaria ME. Xerosis: Treating Clinically Dry Skin. US Pharmacist 2006;31(4):28-32.
  131. Zagaria ME. Parkinson’s Disease: Key Points for the Pharmacist. US Pharcist. 2006;31(3):20-30.
  132. Zagaria ME. Special Considerations for Lowering Lipids in Seniors. US Pharmacist 2006;31(2):20-27.
  133. Zagaria ME. Osteoarthritis in Seniors. US Pharmacist 2006;31(1):20-24.
  134. Zagaria ME. Sleep Disorders in Senior Women: Diagnosing and Treating a Common Complaint. Women’s Health in Psychiatry. 2006;2(1):14-23.
  135. Zagaria ME. Traumatic Brain Injury in the Elderly. US Pharmacist 2005;30(12):20-26.
  136. Zagaria ME. Age-Related Macular Degeneration in the Elderly. US Pharmacist 2005;30(11):30-36.
  137. Zagaria ME. Suppressing Gastric Acid in Seniors with GERD. US Pharmacist 2005;30(10):34-39.
  138. Zagaria ME. Sleep Disturbances in Older Women: Diagnosing and Treating a Common Complaint. Women’s Health in Primary Care. September 2005;8(8):379-386.
  139. Zagaria ME, Buonanno AP. A Patient-Oriented Approach to the Management of Allergic Rhinitis. Power-Pak C.E. Jobson Publishing Group. September 2005.
  140. Zagaria ME. Vaginal Bleeding in Postmenopausal Women. US Pharmacist 2005;30(9):22-26.
  141. Zagaria ME. OTC Medication Use in Seniors. US Pharmacist 2005;30(8):24-26.
  142. Zagaria ME. Tips for Traveling Seniors. US Pharmacist 2005;30(7):32-36.
  143. Zagaria ME. Altered Sleep in Seniors. US Pharmacist 2005;30(6):32-38.
  144. Zagaria ME. The Effects of Aging on Drug Efficacy. US Pharmacist 2005;30(5):54-57.
  145. Zagaria ME. Medication Therapy Management Services. US Pharmacist 2005;30(4):35-42.
  146. Zagaria ME. Abnormal Blood Pressure Homeostasis. US Pharmacist 2005;30(3):29-33
  147. Zagaria ME. Geriatric Syndromes. US Pharm. 2005;30(2):29-34.
  148. Zagaria ME. Implications of Dysphagia. US Pharm. 2005;30(1):30-39.
  149. Cooper CB, Zagaria, ME. New Advances in the Management of COPD. Accreditation Council for Pharmacy Education. Program Number: 809-999-05-001-H01. January 2005.
  150. Perfetto E, Barber A, Atkinson W, Zagaria ME. Monitoring and Evaluation: Demonstrating Improved Care Processes and Patient Outcomes. In: Developing a Senior Care Pharmacy Practice: Your Guide and Tools for Success. 2004. American Society of Consultant Pharmacists. 2004: 123-132
  151. Zagaria ME, Feldman S. Introduction. In: Developing a Senior Care Pharmacy Practice: Your Guide and Tools for Success. 2004. American Society of Consultant Pharmacists. 2004: 5-11.
  152. Zagaria ME. Herpes Zoster, or Shingles, is Painful: Increased Risk in Seniors. US Pharm. 2004;29(12):33-38.
  153. Zagaria ME. Risk in Clinical Trials Versus Clinical Practice: Drug-Induced Hyperkalemia. US Pharm. 2004;11:29-34
  154. Zagaria ME. Low Health Literacy: Raising Awareness for Optimal Health Communication. US Pharm. 2004;29(10):41-48
  155. Zagaria ME. Carpal Tunnel Syndrome: A Major Entrapment Neuropathy in the Elderly. US Pharm. 69. 2004;29(9):30-36
  156. Zagaria ME. Prevention of Prostate Cancer: Study Investigates Vitamin E and Selenium. US Pharm. 2004;29(8):32-38.
  157. Zagaria ME. Managing the Elderly with Stable COPD. US Pharm. 2004;29(7):32-38.
  158. Zagaria ME. Pharmacoeconomics in Senior Care: Balancing Costs and Outcomes. US Pharm. 2004;29(6):32-37.
  159. Zagaria ME. Insomnia, Depression, and Suicide Risk in the Elderly. US Pharm. 2004;29(5):30-37
  160. Zagaria ME. Superficial Fungal Infections: Considerations in Treatment Plans. US Pharm. 2004;29(4):20-24.
  161. Zagaria ME. Seniors as Caregivers. US Pharm. 2005;29(3):16-25.
  162. Zagaria ME. Recommended screenings for older adults. Modern Pharmacy June 2004;11(6):6-7.
  163. Zagaria ME. Hearing loss in the elderly. Modern Pharmacy June 2004;11(6):8-10.
  164. Zagaria ME. Aspirin Resistance. US Pharmacist 2004;29(2):41-46.
  165. Zagaria ME. The Promise of Pharmacogenomics. US Pharmacist 2004;29(1):31-36.
  166. Zagaria ME. Sexually Transmitted Diseases in Older Adults. US Pharmacist 2003;28(12):26-29.
  167. Zagaria ME. Hyperglycemia Due to Atypical Antipsychotics. US Pharmacist 2003;28(11):20-23.
  168. Zagaria ME. Transient Ischemic Attacks. US Pharmacist 2003;28(10):28-31.
  169. Zagaria ME. Dizziness and Vertigo in Seniors. US Pharmacist 2003;28(9):28-32.
  170. Zagaria ME. Benign Prostatic Hyperplasia. US Pharmacist 2003;28(8):28-34.
  171. Zagaria ME. Common Tremors in the Elderly. Modern Pharmacy 2003;10(8):22-24
  172. Zagaria ME. Aspiration Pneumonia. US Pharmacist 2003;28(7):28-33.
  173. Zagaria ME. Hemorrhoids: Treatment Options. US Pharmacist 2003;28(6):28-33.
  174. Zagaria ME. Drug-Induced Acute Renal Failure: Nonsteroidal Anti-Inflammatory Drugs. US Pharmacist 2003;28(5):19-23.
  175. Zagaria ME. Drug-Induced Acute Renal Failure: Angiotensin II Converting Enzyme Inhibitors and Receptor Blockers. US Pharmacist 2003;28(4):29-33.
  176. Zagaria ME. Lumbar Spinal Stenosis. US Pharmacist 2003;28(3):28-30.
  177. Zagaria ME. Hearing Loss in the Elderly. US Pharmacist 2003;28(2):13-15.
  178. Zagaria ME. End-of-Life Care in the Elderly. US Pharmacist 2003;28(1):20-23.
  179. Zagaria ME. Legal Aspects of Eldercare: The Living Will, Healthcare Proxy and Do-Not-Resuscitate (DNR) Order. US Pharmacist 2002;27(12):68-69.
  180. Zagaria ME. Appropriate Monitoring Parameters for Epoetin Alfa Therapy for Anemia Associated with Chronic Renal Failure (CRF). US Pharmacist 2002;27(11):52-54.
  181. Zagaria ME. Postherpetic Neuralgia. US Pharmacist. 2002; 27(10): 21-23.
  182. Zagaria ME. Visual Consequences of the Aging Eye: Falls and Driving Accidents Among Seniors. US Pharmacist. 2002; 27(8): 33-36.
  183. Zagaria ME. Senior Health Maintenance Part II: Cognitive and Nutritional Fitness. US Pharmacist. 2002; 27(7): 21-23.
  184. Zagaria ME. Senior Health Maintenance Part I: Exercise. US Pharmacist. 2002; 27(6): 35-38.
  185. Zagaria ME. Disinhibition as a Complication of Benzodiazepine Therapy. US Pharmacist. 2002; 27(5): 37-41.
  186. Zagaria ME. Recommended Screenings for Older Adults. US Pharmacist. 2002; 27(3): 37-41.
  187. Zagaria ME. Common Tremors in the Elderly: Symptom or Side Effect? US Pharmacist. 2002; 27(1): 23-28.
  188. Zagaria ME. The Elderly Diabetic and Autonomic Neuropathy. US Pharmacist. 2001; 26(11): 28-31.
  189. Zagaria ME. Urinary Incontinence: Care, Complications, and Cost. US Pharmacist. 2001; 26(10): 28-33.
  190. Zagaria ME. Osteoporosis and Prediction of Fracture Risk. US Pharmacist. 2001; 26(09): 28-39.
  191. Zagaria ME. Sciatica in Older Adults. US Pharmacist. 2001; 26(08): 41-46.
  192. Zagaria ME. New Guidelines for Cholesterol Management. US Pharmacist. 2001; 26(07): 29-33.
  193. Zagaria ME. Pharmacist Interventions Can Prevent Falls. US Pharmacist. 2001; 26(05): 79-81.
  194. Zagaria ME. TIA, Stroke, and the Importance of Post-Stroke Rehabilitation. US Pharmacist. 2001; 26(02): 39-40.
  195. Zagaria ME. Alzheimer’s Disease: Focus on Early Diagnosis and Treatment. US Pharmacist. 2001; 26(01): 36-40.
  196. Zagaria ME. Gestational Diabetes Mellitus: Risks, Complications, and Therapeutic Outcomes. US Pharmacist. 2000; 25(11): 50-56.
  197. Zagaria ME. Nutrition in the Elderly: Undernutrition Perpetuates the Process of Physical, Cognitive, and Functional Decline. US Pharmacist. 2000; 25(10): 42-44.
  198. Zagaria ME. Temporal Arteritis: When Headache Can Lead to Blindness. US Pharmacist . 2000; 25 (9): 78-79
  199. Zagaria ME. Actinic Keratosis: Sun Exposure and Cancer Risk. US Pharmacist. 2000; 25 (8): 25-25
  200. Zagaria ME. Avoiding Adverse Effects in the Elderly. US Pharmacist. 2000; 25 (6): 73
  201. Zagaria ME. Insomnia in the Elderly. US Pharmacist. 2000; 25 (5): 81
  202. Zagaria ME. Depression: An Under treated Illness. US Pharmacist. 2000; 25 (4) 111
  203. Zagaria ME. Pain Management. US Pharmacist. 2000; 25 (3) 70-73
  204. Zagaria ME. Pharmaceutical Care of the Older Patient. US Pharmacist. 2000; 25(2): 94-97
  205. Zagaria ME. Quality of Life: Issues for the Pharmacist. American Pharmacy. 1995; NS35:52-58